Patient study ID:									
Date:									
Visit:	Visit 1 *Baseline*	Visit 2 *After cycle 1*	Visit 3 *After cycle 6*	Intermediate visits	Intermediate investigations	End of Treatment (EOT)	End of Study (EOS)	Patient withdrawal	Long-term follow-up
Demography	O								
In- and exclusion criteria	O								
Medical history	O								
Prior systemic therapy for hematological malignancies	O								
Prior stem cell transplantation	O								
Dietary habits	O								
Smoking	O								
Concomitant medication	O	O	O	O	O	O	O	O	
Transfusion requirements	O	O	O	O	O	O	O	O	
Azacitidin medication		O	O	O	O	O	O	O	
Compliance to study treatment (vitamin C/placebo capsules)		O	O	O	O	O	O	O	
Adverse event and serious adverse event		O	O	O	O	O	O	O	
Blood counts and serum chemistry	O	O	O	O	O	O	O	O	
Blood for biobanking - Vitamin C processing & plasma - Biobanking	 O O	 O O	 O O		 O O	 O O	O	 O O	
BM for morphology, cytogenetics and genetics	O		O		O	O			
BM aspirate for biobanking	O	O	O		O	O			
PRO: EORTC QLQ-C30	O	O	O				O	O	
PRO: HM-PRO	O	O	O				O	O	
End of Treatment (EOT) or End of Study (EOS) form						O	O		
Patient withdrawal form								O	
Long-term follow-up form									O